Itraconazol Sandoz

Itraconazole, the active ingredient in Itraconazol Sandoz, is an azole antifungal presented as an oral formulation for systemic use. It treats a range of systemic and superficial fungal infections in adult patients and is prescribed by qualified healthcare professionals.

GNH USA supplies Itraconazol Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Itraconazole is an azole antifungal used to treat infections caused by susceptible fungi. It is indicated for several systemic mycoses: - Invasive aspergillosis: eradicates Aspergillus species in immunocompromised patients. - Blastomycosis: clears Blastomyces dermatitidis infection of lungs and skin. - Histoplasmosis: treats disseminated Histoplasma capsulatum disease. - Coccidioidomycosis: resolves Coccidioides immitis infection of respiratory tract. - Sporotrichosis: eliminates Sporothrix schenckii in cutaneous and disseminated forms.

Adverse reactions may occur with itraconazole therapy.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Vomiting: occasional emesis. - Abdominal pain: cramping or discomfort. - Headache: transient tension‑type headache. - Rash: mild skin erythema or pruritus. - Taste disturbance: altered or reduced taste perception.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or hepatitis. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Cardiac failure: worsening of pre‑existing heart conditions. - Visual disturbances: blurred vision or photophobia. - QT prolongation: potential arrhythmia risk. - Severe liver injury: hepatic failure requiring medical intervention.

Before initiating itraconazole, clinicians should consider several safety measures. - Assess liver function: obtain baseline hepatic enzymes. - Monitor cardiac status: avoid in patients with known heart failure. - Check for hypersensitivity: discontinue if allergic reaction occurs. - Review concomitant medications: avoid strong CYP3A4 inhibitors. - Adjust dose in hepatic impairment: follow clinical guidelines. - Store at room temperature: keep in the original container, protect from moisture and light.

Itraconazole has a notable potential for drug‑drug interactions.

Major Interactions (Avoid): - Ketoconazole: combined azole therapy increases toxicity risk. - Rifampin: induces metabolism, markedly reducing itraconazole levels. - Ritonavir: potent CYP3A4 inhibitor leading to dangerous itraconazole accumulation.

Moderate Interactions (Monitor Closely): - Cimetidine: may increase itraconazole plasma concentrations. - Warfarin: enhanced anticoagulant effect requiring INR monitoring.